Evaluation of surrogacy in the multi-trial setting based on information theory:an extension to ordinal outcomes by Ensor, Hannah & Weir, Christopher J
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of surrogacy in the multi-trial setting based on
information theory
Citation for published version:
Ensor, H & Weir, CJ 2019, 'Evaluation of surrogacy in the multi-trial setting based on information theory: an
extension to ordinal outcomes', Journal of biopharmaceutical statistics, pp. 1-13.
https://doi.org/10.1080/10543406.2019.1696357
Digital Object Identifier (DOI):
10.1080/10543406.2019.1696357
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of biopharmaceutical statistics
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=lbps20
Journal of Biopharmaceutical Statistics
ISSN: 1054-3406 (Print) 1520-5711 (Online) Journal homepage: https://www.tandfonline.com/loi/lbps20
Evaluation of surrogacy in the multi-trial setting
based on information theory: an extension to
ordinal outcomes
Hannah Ensor & Christopher J. Weir
To cite this article: Hannah Ensor & Christopher J. Weir (2019): Evaluation of surrogacy in
the multi-trial setting based on information theory: an extension to ordinal outcomes, Journal of
Biopharmaceutical Statistics, DOI: 10.1080/10543406.2019.1696357
To link to this article:  https://doi.org/10.1080/10543406.2019.1696357
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 30 Dec 2019.
Submit your article to this journal 
Article views: 102
View related articles 
View Crossmark data
Evaluation of surrogacy in the multi-trial setting based on
information theory: an extension to ordinal outcomes
Hannah Ensor and Christopher J. Weir
Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
ABSTRACT
Summary: In clinical trials, surrogate outcomes are early measures of treat-
ment effect that are used to predict treatment effect on a later primary
outcome of interest: the primary outcome therefore does not need to be
observed and trials can be shortened. Evaluating surrogates is a complex
area as a given treatment can act through multiple pathways, some of
which may circumvent the surrogate. One of the best established and
practically sound approaches to surrogacy evaluation is based on informa-
tion theory. We have extended this approach to the case of ordinal out-
comes, which are used as primary outcomes in many medical areas. This
extension provides researchers with the means of evaluating surrogates in
this setting, which expands the usefulness of the information theory
approach while also demonstrating its versatility.
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1. Introduction
It is legitimate to use a surrogate in place of the true or primary outcome of interest in a clinical trial if it
can be established that it informs on the treatment effect on the true outcome. In so doing, a clinical trial
can be conducted with a smaller sample size and efficacious treatments can be made available to patients
in a more timely fashion. However, the confidence placed in a “legitimate” surrogate can only be as
strong as the means of establishing its validity. Baker and Kramer (2003) stated that where treatments
work through multiple pathways (as is often the case) surrogacy assessment is difficult. Many different
approaches for the evaluation of surrogates have been suggested (Alonso and Molenberghs 2007;
Frangakis and Rubin 2004; Molenberghs et al. 2008; Robins and Greenland 1992). For a systematic
review of methods see Ensor et al. (2016). These tend to examine whether surrogates are informative at
both the individual patient level and the clinical trial level.
The work presented here aims to extend multi-trial information theory-based surrogate evalua-
tion to the case of ordinal outcomes. In so doing we allow researchers to evaluate surrogates in areas
where ordinal outcomes are used, for instance in stroke where the Oxford Handicap Scale (Bamford
et al. 1989) is often measured.
Various existing surrogate evaluation approaches could be extended to the case of ordinal
outcomes, including the direct and indirect effects, principal stratification and information theory
approaches (Alonso and Molenberghs 2007; Frangakis and Rubin 2004; Robins and Greenland
1992). Aside from quantitatively evaluating the potential surrogate, we would wish any such
approach to have four main properties. An approach should be: (a) practically viable; (b) able to
inform on the causal nature of relationships between the surrogate and true outcome; (c) able to
identify the surrogate paradox. The surrogate paradox occurs when there are positive treatment
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effects on the surrogate, and a positive relationship between the surrogate and true outcome, but
a negative treatment effect on the true outcome; and (d) inform on the surrogate’s transport-
ability or predictive ability, a fundamental requirement of surrogacy whereby surrogates evaluated
in one trial would be able to inform on the treatment effect on the true outcome in a new trial.
Pragmatic multi-trial approaches, including meta-analytical (Buyse et al. 2000) and information
theory (Alonso and Molenberghs 2007) are well-established methods that fulfil to a good standard all
the above criteria. Therefore, we consider the multi-trial approaches to be the most appropriate for
extension to ordinal outcomes. These approaches assess surrogacy at two levels: the individual patient
and trial levels. In simple terms, correlation is an insufficient measure of surrogacy because it ignores
treatment mechanisms of action and can lead to the surrogate paradox. In multi-trial approaches, the
individual patient measure of surrogacy is essentially a correlation but treatment allocation is taken into
account. At the trial level, multi-trial approaches provide a measure of the predictive ability of the
surrogate to determine whether a surrogate could inform on the likely treatment effect on the primary
outcome in a new trial, i.e. its transportability. This satisfies one of the primary aims of a valid surrogate.
Combined these measures provide a methodologically sound and practically useful assessment of
surrogacy that goes beyond a simple measurement of correlation.
The multi-trial information theory approach has fewer computational and interpretational issues
compared to earlier multi-trial approaches and provides consistent interpretation across settings (for
example, ordinal or continuous outcomes) (Alonso and Molenberghs 2007). Given these strong
methodological and practical advantages, we select the multi-trial information theory approach here
for extension to the case of ordinal outcomes.
Most methodology developed for ordinal outcomes has been in early surrogate evaluation measures
such as single trial studies (Molenberghs et al. 2001) or the multi-trial (meta-analytical) approach
(Burzykowski et al. 2003; Molenberghs et al. 2002; Renard et al. 2002); none have been evaluated via
simulation. Under the meta-analytical approach Renard et al. (2002) briefly outline a latent variable
approach; Burzykowski et al. (2003) present methodology for an ordinal surrogate and time to event
true outcome; and Alonso et al. (2002) investigate the setting where one of the surrogate or true
outcome is ordinal and the other continuous. In contrast, our work provides a fully developed
methodological extension to the ordinal case in the multi-trial setting, building on the established
strengths of the information theory approach to surrogacy evaluation. This has been evaluated by an
extensive simulation study incorporating many settings not investigated previously, including weak
strengths of surrogacy; discordant strengths of surrogacy at trial and individual levels; ceiling effects for
categorical outcomes; as well as an investigation of the impact of non-proportional odds.
In Section 2 we outline the information theory approach and how this can be extended to the case of
ordinal outcomes. We cover the “binary-ordinal” setting where the surrogate is binary and the true
outcome ordinal; the theory developed could also be applied to the ordinal-ordinal setting with some
minor modifications. Section 3 presents a simulation study to evaluate the properties of the ordinal
extension. Section 4 illustrates the method using a case study from the stroke clinical trial CLOTS3
(Dennis et al. 2015) and Section 5 discusses our methodology extension in the broader context.
2. Methods
In what follows, the surrogate is denoted S, treatment is Z and the true outcome is T. There
are i = 1,2, …,N trials, and j = 1,2, … .,ni patients per trial. NT ¼
P
i ni is the total number of
patients in all trials. The ordinal true outcome has Wordered categories.
2.1. The information theory approach
Alonso and Molenberghs (2007) proposed an information theory surrogate evaluation measure based
on the concepts of entropy and information theory by Shannon (1948). Information theory uses the
central concept of entropy to measure the “information, choice and uncertainty” in a random variable.
2 H. ENSOR AND C. J. WEIR
In the discrete case, entropy can be represented as H Yð Þ ¼ Pmyb¼ 1 pblog pbð Þ, where Y is a discrete
random variable with values k1; k2; . . . :; kmy and probabilities p1; p2; . . . :; pmy respectively.
Conditional;H YjXð Þ, and joint entropy, H Y;Xð Þ, can be straightforwardly defined. And differential
entropy measures information in the continuous case, hd Yð Þ ¼  11 fy yð Þ log fy yð Þ
 
dy.
A concept of fundamental importance is the mutual information. This is defined as I X;Yð Þ ¼
H Yð Þ HðYjXÞ and is interpreted as the amount of uncertainty in Y removed if X is known.
Another useful concept for comparing random variables is the entropy power, obtained by max-
imising the entropy of a continuous random variable, defined as EP Yð Þ ¼ 12πeð Þ e2h Yð Þ. See Shannon
(1948) for a full list of the properties of entropy and the mutual information.
These concepts are useful in surrogate evaluation as, at the individual level, we are interested in
the amount of information on T (or ‘treatment effects on T’ at the trial level) covered by our
knowledge of S (or ‘treatment effects on S’ at the trial level).
2.1.1. Individual level: information theory approach
At the individual level, Alonso and Molenberghs (2007) proposed an information theory surrogate
evaluation measure:
R2h ¼
EP Tð Þ  EP TjSð Þ
EP Tð Þ (1)
where EP Tð Þ is the entropy power of T and EP TjSð Þ is the entropy power of T given S. This can be
interpreted as the amount of uncertainty in the true outcome T removed when S is known. R2h has
useful properties: it is linked to the mutual information through R2h ¼ 1 e2I S;Tð Þ; R2h is invariant by
bijective transformations of S and T; and R2h ¼ 0 if and only if T and S are independent.
Alonso and Molenberghs (2007) suggested a multi-trial framework R2h: as shown in Equation (2)
to enable transportability of results for the information theory approach.
R2h ¼
XNq
i¼1 #iR
2
hi ¼ 1
XNq
i¼1 #ie
2Ii si;tið Þ;
where
#i > 0"i;
XNq
i¼1 #i ¼ 1 (2)
For N trials there are Nq possible values of R2hi , the R
2
h for the i
th trial since trials can be clustered
depending, say, on q different characteristics (e.g. centre, country, treating physician). There are
many different choices for the set of unknown weights, #i in (2). The choice of which leads to an
uncountable set of parameters, Ωh, each parameter of which could act as a single meaningful
measure of R2h in the multi-trial setting:
Ωh ¼ Φh : Φh ¼ 1
XNq
i¼1
#ie
2Ii Si;Tið Þ
i ;where#i > 0"i;
XNq
i¼1 #i ¼ 1
( )
(3)
whereΦh are the parameters of the set Ωh. Alonso and Molenberghs (2007) highlighted the likelihood
reduction factor (LRF) as a good candidate fromΩh which provides a useful route to defining
PNq
i¼1 #i.
The LRF is a measure of information gain that has been considered under an information theory
framework by several authors (Brillinger 2004; Joe 1989; Kullback 1997; Linfoot 1957).
The LRF is particularly useful for surrogacy evaluation as it ranges in the unit interval and has
a consistent interpretation across settings: this is a key point as previous approaches could not
provide this. Furthermore, it is possible that a high-dimension integral would be needed in the
calculation of I(T,S) which the LRF avoids, and as we will expand on in section 2.1.1.1 the LRF
provides consistent estimation of R2h (Alonso et al. 2016; Alonso and Molenberghs 2007). Finally,
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previous approaches to surrogacy assessment relied on computationally intensive joint models of
S and T, but the LRF assesses just the conditional model of T|S and the marginal model of T and
hence avoids this issue.
2.1.1.1. LRF at the individual level: the continuous setting. The LRF was proposed by Alonso et al.
(2006) based on the ideas of Kent (1983). At the individual level, the LRF is based on the amount
of information gained about the true outcome after accounting for the surrogate which was
proposed as a general measure of correlation. Alonso et al. (2005) proposed modelling (4) and
(5) for each trial i (linear models are presented here, whereas generalised linear models were
originally given):
Tij ¼ μi þ βiZij þ εTij (4)
Ti ¼ θ0i þ θ1iZij þ θ2i Sij þ εTjSij (5)
where: θ0i and μi are intercept parameters with and without adjustment for the surrogate; βi is the
treatment effect parameter for the true outcome; θ1i and θ2i are treatment and surrogate parameters
for the model with adjustment for the surrogate. The amount of information on the true outcome
gained from the surrogate is calculated via the difference in the log-likelihood between (4) and (5)
which is formally expressed as G2i , for each trial i. LL0 is the log-likelihood for the unsaturated
model, in this case (4), and LL1 for the saturated model, (5), for trial i. G2i ¼ 2 LL1  LL0ð Þ.
The LRF is then calculated:
LRF ¼ 1 1
N
XN
i¼1 exp 
G2i
ni
 
(6)
To demonstrate the link between the LRF and R2h, consider the i
th trial and joint density function
f ðTi; SijθiÞ of Ti; Sið Þ, where we have θi ¼ θi ; θ2ið Þ. Where θ2i represents the dependence between
S and T, θ^i is the maximum likelihood estimator under the null hypothesis of independence
(θ2i ¼ 0), and θ^i is the maximum likelihood estimator for the saturated model. We can express
1
ni
G2i ¼ 1ni
P
i½logff ðtijsi;bθiÞg  log f tij bθi n o. If bθi converges to θi in probability then
1
ni
G2i ! Ii Si;Tið Þ under general regularity conditions, hence 1ni G2i is a consistent estimator
of Ii Si;Tið Þ.
Using the estimator 1ni G
2
i of Ii Si;Tið Þ we have LRF ¼ R^2h ¼ 1
PNq
i¼1
1
N e
 1niG
2
i , which is a special
case of R2h in (3) where #i ¼ 1N :Therefore, the LRF is a consistent estimator of R2h (Alonso and
Molenberghs 2007; Brillinger 2004). For a full proof see the supplementary material of (Alonso and
Molenberghs 2007).
2.1.1.2. LRF at the individual level: extension to the binary-ordinal setting. The LRF can be used
to calculate R2h for a binary surrogate and ordinal true outcome. At the individual level, the LRF
can be applied in the binary-ordinal setting in the same manner as in the continuous case using
(6), based in this case on the difference G2 ¼ 2 LL1  LL0ð Þ of the following proportional odds
models:
logit P Tij  w
 	  ¼ μTwi þ βiZij (7)
logit P Tij  w
 	  ¼ θ0wi þ θ1iZij þ θ2i Sij (8)
where w ¼ 1; . . . :;W  1, and W is the number of categories in the ordinal true outcome. For trial i,
μTwi
and θ0wi are intercept parameters for each cut point of the ordinal true outcome, βi and θ1i
represent the treatment effect on the true outcome and θ2i is the surrogate parameter. Again, the LRF
is based on the amount of information gained on the true outcome after adjusting for the surrogate
for each trial.
4 H. ENSOR AND C. J. WEIR
However, in the case of discrete outcomes and a family of conditional models, the LRF is bounded
above by a number strictly less than one (Kent 1983). Alonso and Molenberghs (2007) showed that
R2h  1 e2H Tð Þ, where H(T) represents the entropy of T. They also suggested that H(T) can be
approximated based on the log-likelihood of the intercept-only model of true outcome
(logit P Tij  w
 	  ¼ θ3, where θ3 is the intercept parameter). Alonso and Molenberghs (2007)
therefore proposed rescaling R2h as calculated by the LRF in (6) by:
cR2h ¼ R2h1 e2H Tð Þ (9)
The LRF thus gives a consistent interpretation at the individual level for both the binary-ordinal and
continuous settings.
2.1.2. Trial level: information theory approach
At the trial level, interest is in the relationship between treatment effects on the surrogate and
treatment effects on the true outcome. Alonso and Molenberghs (2007) proposed a two-stage
approach. At the first stage, the treatment effects for each trial on the surrogate and true outcome
are obtained, αi and βi respectively. This is done by regressing the surrogate and true outcome on
treatment in separate models:
Sij ¼ μSi þ αiZij þ εSij (10)
Tij ¼ μTi þ βiZij þ εTij (11)
where μSi ; μTi ; represent the mean intercept and αi; βi the treatment effects for S and T, respectively.
Using the treatment effect estimates for S and T from these models, α^i and β^i respectively, we
calculate the information theory surrogacy measure R2ht; where the subscript t indicates that we are
now considering trial-level surrogacy, through:
R2ht ¼
EP β^
 
 EP β^jα^
 
EP bβ  (12)
where EP β^
 
is the entropy power of the distribution of treatment effect estimates on T across
the i trials and EP β^jα^
 
is the entropy power of the distribution of treatment effect estimates on
T given those on S. R2ht can be interpreted as the amount of uncertainty in the treatment effect on
T removed through knowledge of the treatment effect on S.
2.1.2.1. The LRF at the trial level: the continuous setting. The LRF can be applied to calculate R2ht
in the continuous-continuous case. In order to do this (10) and (11) are again modelled to obtain
treatment estimates α^i and β^i and μ^Si . At the second stage, two further models of the treatment effect
on the true outcome are required:
β^i ¼ γ3 þ εβi (13)
β^i ¼ γ0 þ γ1μ^Si þ γ2α^i þ εβjμ;αi (14)
where γ3 and γ0 are the intercept parameters with and without adjustment for the surrogate
treatment effects and γ1 and γ2 are the parameters for the surrogate intercept and treatment effect
estimates provided from stage one. The difference in log-likelihood between these two models can
then be calculated and the LRF applied as in (15).
LRF ¼ cR2ht ¼ 1 exp G2N
 
(15)
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In a similar fashion to the LRF at the individual level, it can be shown that the LRF is a consistent
estimator of R2ht (Alonso et al. 2016).
2.1.2.2. The LRF at the trial level: extension to the binary-ordinal setting. In the binary-ordinal
setting, the key difference in the approach is in the models used at the first stage. Here a generalised
linear and proportional odds model are required for the surrogate and true outcome, respectively:
logit PðSij ¼ 1Þ
  ¼ μSi þ αiZij (16)
logit PðTij  wÞ
  ¼ μTwi þ βiZij (17)
where w ¼ 1; . . . :;W  1, and W is the number of categories in the ordinal true outcome, μTwi is
the set of intercept parameters for each of the W-1 cut points of the ordinal true outcome and all
other parameters are analogous to the continuous case. The second stage models (13) and (14) can
be fitted in the same manner as in the continuous setting using the parameters of (16) and (17), and
the LRF applied as in (15). The LRF has a consistent interpretation at the trial level for the
continuous-continuous and binary-ordinal settings, and it can easily be seen how this would be
the case for other settings.
2.2. Confidence intervals – all settings
A confidence interval based on the non-central χ2 distribution forR2ht may be calculated as per (Kent 1983):
1 exp  γ1:α=2 G
2ð Þ
N
 !
; 1 exp  δ1:α=2 G
2ð Þ
N
 ( )
where γ1:α and δ1:α are defined by χ
2
1 γ1:α G
2ð Þ   G2
  ¼ αand P χ21 δ1:α G2ð Þf g  G2
  ¼ α; and χ21
represents the non-central chi-squared distribution with 1 degree of freedom. The above is true
unless P χ21 0ð Þ  G2
 
> α in which case γ1:α G
2ð Þ ¼ 0.
R2h on the other hand has multiple G
2
i . Previous publications have computed non-parametric
bootstrap confidence intervals in this setting and we follow that methodology (Alonso et al. 2006).
3. Simulation study
3.1. Set-up
The practical worth of the approach is demonstrated via a thorough simulation study using R, based
on the approach of (Tilahun et al. 2008). Different scenarios were simulated to see how the R2
measures perform when different numbers of trials and sizes of trial are available. We reported the
median point estimate and median upper and lower confidence limits over 250 simulations for each
scenario investigated. We use the methodology of the precursor to the information theory approach,
the meta-analytical approach, to set up the simulation as conducted by many previous authors
Tilahun et al. (2008). The normal joint mixed model (17) gives the basis for the data generation:
Sij ¼ μS þmSi þ αZij þ aiZij þ εSij (18)
Tij ¼ μT þmTi þ βZij þ biZij þ εTij
where ðμs, μT) and (α, β) are fixed intercepts and treatment effects, respectively. (mSi ;mTiÞ and
ðai; bi) are random intercepts and treatment effects for the ith trial, respectively. ðεSij ,εTijÞ ~ Nð0;
PÞ
and random effects, mSi ;mTi ; ai; bið ÞT ~ N 0;Dð Þ, where:
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D ¼ 3
1 075 0 0
0:75 1 0 0
0 0 1 ρ
0 0 ρ 1
0BB@
1CCA;whereR2ht ¼ ρ2;
X
¼ 3 1 ψ
ψ 1
 
;whereR2h ¼ ψ2:
Specific values of D and
P
were chosen in line with Tilahun et al. (2008) as were individual trial
intercept and treatment parameters for S and T which were set to μs= 0.50, μT= 0.45, α = 0.05, and
β = 0.03. Their values do not influence the true strength of surrogacy.
Four surrogacy scenarios were simulated: strong, with R2ht ¼ ρ2 ¼ 0:90 and R2h ¼ ψ2 ¼ 0:64;
weak, with R2ht ¼ ρ2 ¼ 0:30 and R2h ¼ ψ2 ¼ 0:30; or to have discordant levels of surrogacy at trial
and individual level, R2ht ¼ ρ2 ¼ 0:90 and R2h ¼ ψ2 ¼ 0:30; or R2ht ¼ ρ2 ¼ 0:30 and R2h ¼ ψ2 ¼ 0:64.
After simulating a continuous S and T these were then dichotomised or categorised to represent
a binary S and ordinal T. T was set to have seven categories and its distribution was simulated to
follow what might be observed in the Oxford Handicap Scale (Van Swieten et al. 1988) investigated
in the stroke case study (section 4). We also investigate the setting where the ordinal outcome does
not fulfil the proportional odds assumption, by changing for one treatment arm one of the quantiles
at which the continuous T is cut to generate the ordinal categorical T. Trial sizes were set to 60, 100,
and 300 patients. There were 5, 10, 20 or 30 trials in each simulated data set. There were 250 datasets
simulated for each scenario: a total of 15,000 simulations covering all combinations of the strength of
surrogacy (4), trial size (3) and number of trials (4) scenarios and in addition the non-proportional
odds setting with strong surrogacy for all trial size and number of trials scenarios.
At the individual level in the discrete binary-ordinal case, information theory explores surrogacy
at the observed rather than latent scale, and therefore the strength of surrogacy is expected to be
lower than on the latent continuous level (Tilahun et al. 2008). This reflects reality, since for example
binary measures often represent latent continuous variables and a binary surrogate would be
expected to provide less information than a continuous one. Therefore, we expect the maximum
surrogacy strength achievable in the observed binary-ordinal setting to be much lower than the ‘true’
strength of surrogacy set at the latent level. We investigated the individual level surrogacy ceiling for
a binary surrogate with an ordinal true outcome by further investigating the ideal scenario where
R2ht ¼ ρ2 ¼ 0:90 and R2h ¼ ψ2 ¼ 1. In this case, 250 data sets were simulated for each scenario: a total
of 3,000 simulations covering all combinations of the trial size (3) and number of trials (4) scenarios.
3.2. Results
For strong surrogacy cR2h converges to around 0.30 (Table 1) for larger numbers of trials and trial
sizes; this is much lower than the 0.64 strength simulated on the latent continuous scale. Equally, for
weak surrogacy cR2h converges to around 0.13 (Table 2) which is again much lower than the strength
of 0.30 simulated on the latent scale. Simulations for the ‘perfect’ surrogate with R2h = 1 converge to
around cR2h = 0.48, the ceiling for this binary surrogate for an ordinal true outcome generated from
a latent continuous measure, see Table 3.
Unlike individual-level surrogacy, trial-level surrogacy, R2ht, ought to report the same surrogacy strength
at the latent and explicit scales (Tilahun et al. 2008). However, there appears to be some underestimation ofcR2ht for strong surrogacy even where trial sizes are large (Table 1). This is in line with results in the
continuous-binary and binary-binary settings (Pryseley et al. 2007; Tilahun et al. 2008). Conversely, where
surrogacy is set to be weak (Table 2) there is overestimation of R2ht for small trial sizes. Further examination
showed this was due to overfitting to the resultant small number of data points (one for each trial) in the
regression model used at the second stage of R2ht modelling.
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cR2ht and cR2h estimates where surrogacy strengths differ at trial and individual levels are similar to
where surrogacy strengths are consistent, see Table 4. Deviation from the proportional odds
assumption also seems to have little impact on results at either level, see Table 5.
4. Case study – CLOTS3
The case study, conducted using data from the randomised trial Clots in Legs Or sTockings after
Stroke (CLOTS) 3 trial (Dennis et al. 2015), aimed to determine whether measures taken within 30
days of a stroke could be used as a surrogate in place of death and disability measured 6 months post
stroke.
Venous thromboembolism encompasses the ailments: deep vein thrombosis (DVT), a blood clot
in the deep veins of the legs; and pulmonary embolism (PE), where clots detach from the veins and
Table 1. Simulation study results: Strong surrogacy. True values on the latent continuous scale used to generate
data are trial-level surrogacy R2ht = 0.90, and individual-level surrogacy R
2
h = 0.64 (at the individual level we expect
strength of surrogacy in the binary-ordinal setting to be low due to loss of information from moving from
continuous to categorical outcomes). 250 simulations were performed for each of the scenarios reported in the
table. We present the number and size of trials simulated; the median R2 of the 250 simulations; median lower and
upper limits of the 95% confidence intervals.
R2ht : Trial-level surrogacy R
2
h : Individual-level surrogacy
Number
of trials Trial size Median cR2ht Lower 95%CI Upper95%CI Median bR2h Lower 95%CI Upper95%CI
5 60 0.930 0.404 0.998 0.308 0.228 0.398
5 100 0.934 0.429 0.998 0.307 0.242 0.371
5 300 0.948 0.501 0.999 0.305 0.267 0.343
10 60 0.833 0.349 0.982 0.304 0.245 0.367
10 100 0.847 0.411 0.983 0.298 0.252 0.344
10 300 0.895 0.541 0.989 0.299 0.271 0.325
20 60 0.793 0.454 0.952 0.297 0.257 0.341
20 100 0.826 0.522 0.960 0.300 0.268 0.334
20 300 0.871 0.622 0.970 0.293 0.274 0.312
30 60 0.783 0.512 0.929 0.297 0.263 0.332
30 100 0.823 0.588 0.944 0.296 0.270 0.323
30 300 0.866 0.668 0.958 0.293 0.278 0.310
Table 2. Simulation study results: weak surrogacy. True values on the latent continuous scale used to generate
data are trial-level surrogacy R2ht = 0.30, and individual-level surrogacy R
2
h = 0.30 (at the individual level we expect
strength of surrogacy in the binary-ordinal setting to be low due to loss of information from moving from
continuous to categorical outcomes). 250 simulations were performed for each of the scenarios reported in the
table. We present the number and size of trials simulated; the median R2 of the 250 simulations; median lower and
upper limits of the 95% confidence intervals for the 250 simulations.
R2ht : Trial-level surrogacy R
2
h : Individual-level surrogacy
Number
of trials Trial size
MediancR2ht Lower 95%CI Upper95%CI MedianbR2h Lower 95%CI Upper95%CI
5 60 0.643 0.028 0.974 0.143 0.086 0.231
5 100 0.682 0.039 0.979 0.140 0.092 0.204
5 300 0.670 0.038 0.977 0.135 0.107 0.171
10 60 0.429 0.012 0.866 0.144 0.104 0.206
10 100 0.393 0.009 0.843 0.137 0.105 0.183
10 300 0.385 0.009 0.832 0.134 0.113 0.158
20 60 0.265 0.010 0.656 0.138 0.114 0.183
20 100 0.303 0.021 0.676 0.136 0.115 0.170
20 300 0.311 0.027 0.673 0.131 0.118 0.149
30 60 0.243 0.019 0.568 0.141 0.122 0.179
30 100 0.271 0.033 0.589 0.136 0.119 0.164
30 300 0.304 0.054 0.610 0.132 0.121 0.147
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cause blockages to the lungs. Venous thromboembolism can be serious enough to cause death or be
so debilitating it hinders rehabilitation. Dennis et al. (2013) showed that 20–42% of stroke patients
suffer a venous thromboembolism. This result reflects the fact that stroke patients are typically
bedbound and often unable to move one side of their body.
A primary measure of ongoing health and survival measured in patients 6 months post stroke is
the Oxford Handicap Scale (OHS) (Van Swieten et al. 1988). This is an ordinal measure on a seven-
point scale, ranging from no symptoms up to severe disability and death.
CLOTS3 was a 94 centre randomised clinical trial with 2,876 patients. It was conducted to
investigate whether intermittent pneumatic compression (IPC) applied to the legs of acute stroke
patients reduced the occurrence of DVT (Dennis et al. 2015). CLOTS3 () showed that IPC reduced
the odds of DVT by 30 days [OR 0.65 (95% CI 0.51–0.84; p = .001) after adjustment for baseline
variables] and had a positive impact on survival at 6 months, HR 0.86 (0.74–0.99), p = .042.
Table 3. Simulation study results: Ceiling effect. True values on the latent continuous scale used to
generate data are trial-level surrogacy R2ht = 0.90, and individual-level surrogacy R
2
h = 1 (at the individual
level we expect strength of surrogacy in the binary-ordinal setting to be low due to loss of information
from moving from continuous to categorical outcomes). 250 simulations were performed for each of the
scenarios reported in the table. We present the number and size of trials simulated; the median R2 of the
250 simulations; median lower and upper limits of the 95% confidence intervals for the 250 simulations.
Individual-level surrogacy
Number
of trials Trial size Median bR2h Lower 95%CI Upper95%CI
5 60 0.539 0.398 0.599
5 100 0.548 0.429 0.598
5 300 0.516 0.444 0.569
10 60 0.514 0.419 0.562
10 100 0.510 0.426 0.556
10 300 0.484 0.424 0.540
20 60 0.492 0.425 0.527
20 100 0.500 0.441 0.535
20 300 0.489 0.438 0.520
30 60 0.494 0.438 0.521
30 100 0.488 0.439 0.517
30 300 0.478 0.438 0.508
Table 4. Simulation study results: differing strengths of surrogacy against the case where surrogacy is
strong at both levels. 250 simulations were performed for each of the scenarios reported in the table. We
present the number and size of trials simulated; and the median R2 of the 250 simulations. ¥ Both
comparisons are between strong level surrogacy at both levels, R2ht ¼ 0:90 and R2h = 0.64, against the
case where surrogacy is strong at the level under consideration but weak (either R2ht ¼ 0:30 or R2h = 0.30) at
the unreported level. The converse case gives comparable results (results not shown).
Median cR2ht¥
Trial-level surrogacy
Median bR2h ¥
Individual-level surrogacy
Number
of trials Trial size R2ht ¼ 0:90 R2h = 0.64
R2ht ¼ 0:90
R2h = 0.30 R
2
ht ¼ 0:90 R2h = 0.64 R2ht ¼ 0:30 R2h = 0.64
5 60 0.930 0.905 0.308 0.303
5 100 0.934 0.934 0.307 0.308
5 300 0.948 0.951 0.305 0.302
10 60 0.833 0.823 0.304 0.294
10 100 0.847 0.851 0.298 0.293
10 300 0.895 0.895 0.299 0.291
20 60 0.793 0.750 0.297 0.292
20 100 0.826 0.811 0.3 0.290
20 300 0.871 0.865 0.293 0.287
30 60 0.783 0.734 0.297 0.291
30 100 0.823 0.803 0.296 0.291
30 300 0.866 0.861 0.293 0.288
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Weused this data set to assess whether the occurrence of DVT, PE or death within 30 days is a surrogate
for OHS at 6 months. The information theory approach was applied to investigate this and we used study
centres in place of trials (Abrahantes et al. 2004). The results shown in Table 6 and Figure 1 indicate that
DVT is not a good surrogate for OHS, ascR2h is 0.173 95% CI (0.141, 0.188) and cR2ht is 0.186 95% CI (0.048,
0.374). While there is no established cut-off corresponding to a ‘valid’ surrogate previous publications have
suggested that surrogates that exceed 0.80 at both levels can be deemed valid, while if surrogacy strength at
either level is below 0.50 surrogacy strength is poor (Alonso et al. 2016). Therefore, these results suggest
a poor surrogate.
A sensitivity analysis was conducted to assess whether the potential bias witnessed in the
simulation study (where underestimation increased with increased number of trials) may have
influenced our results. We regrouped centres so there were fewer groups (results not shown), and
we found that while some level of underestimation had taken place the point estimates were still
comfortably under 0.50 and therefore our conclusions did not change. Further information on the
case study is provided in Appendix A.
5. Discussion
The information theory approach of Alonso and Molenberghs (2007) has previously been extended
to failure time outcomes (Pryseley et al. 2011); repeated measures (Alonso et al. 2006); a continuous
surrogate and binary true outcome (Pryseley et al. 2007); and binary outcomes (Tilahun et al. 2008).
This paper complements these by extending the methodology to the case of a binary surrogate and
an ordinal true outcome.
A major strength of the work presented is the wide range of scenarios considered in the
simulation study that evaluated the performance of the extended methodology measures of
Table 6. CLOTS3 case study results: Information theory
surrogacy estimates for binary DVT surrogate and ordinal
OHS true outcome; analysed using a modified information
theory approach incorporating a penalized likelihood
approach (Firth 1993) to deal with the issue of sparse data.
R2h Individual level R
2
ht Trial level
0.173 0.186
95% CI (0.141, 0.188)) 95% CI (0.048,0.374)
Table 5. Simulation study results: considering proportional versus non-proportional odds. True values on the
latent continuous scale used to generate data are trial-level surrogacy R2ht = 0.90, and individual-level surrogacy R
2
h
= 0.64. 250 simulations were performed for each of the scenarios reported in the table. We present the number
and size of trials simulated; and the median R2 of the 250 simulations.
Median cR2ht
Trial-level surrogacy
Median bR2h
Individual-level surrogacy
Number
of trials Trial size Proportional
Non-
Proportional Proportional
Non-
Proportional
5 60 0.930 0.925 0.308 0.305
5 100 0.934 0.928 0.307 0.308
5 300 0.948 0.947 0.305 0.304
10 60 0.833 0.823 0.304 0.301
10 100 0.847 0.845 0.298 0.292
10 300 0.895 0.890 0.299 0.295
20 60 0.793 0.788 0.297 0.295
20 100 0.826 0.818 0.3 0.295
20 300 0.871 0.866 0.293 0.291
30 60 0.783 0.772 0.297 0.294
30 100 0.823 0.818 0.296 0.293
30 300 0.866 0.862 0.293 0.290
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individual-level surrogacy, R2h, and trial-level surrogacy, R
2
ht in the binary-ordinal context. Extending
previous simulation studies in this area (Tilahun et al. 2007, 2008) we assessed weak strengths of
surrogacy, discordant levels of surrogacy at trial and individual levels and investigated the ceiling
effect present when using binary and ordinal outcomes. We also completed the first assessment via
simulation of the non-proportional odds scenario for ordinal outcomes. A further benefit was the
opportunity to provide a clear answer to a question of clinical interest regarding deep vein
thrombosis, DVT, as a potential surrogate for long-term outcome following stroke the Oxford
Handicap Scale, OHS, using data from the CLOTS (Dennis et al. 2015) randomised controlled trial.
As might have been expected, the simulation study showed that a binary surrogate is less
informative than its latent counterpart at the individual level; the ceiling for the binary-ordinal
setting is around half the strength of that simulated on the underlying continuum.
Some unexpected underestimation of R2ht was observed; we speculate that this is due to ineffi-
ciencies in estimation through a combination of the use of a two-stage estimation approach and the
involvement of discrete outcomes. Furthermore, overestimation of R2ht occurred for weak surrogacy
and small numbers of trials, due to overfitting at the second stage of modelling. Assessments of
surrogates of this kind might lead researchers to believe incorrectly that they are valid. This is likely
to be an issue regardless of the setting (binary-continuous, continuous-continuous etc.) and has not
previously been identified. These two sources of bias at the trial level, overfitting and inefficiency,
point to some practical issues with the two-stage modelling approach and require further investiga-
tion. Deviations from the proportional odds assumption or discordant surrogacy strength at trial and
individual levels had little impact on cR2ht orcR2h results with positive implications for the robustness of
this surrogacy assessment approach.
In future work, it would be interesting to study the underestimation found in this work in more
detail – perhaps in the context of contrasting settings, e.g. time-to-event or repeated measures.
Nevertheless, if inefficiency is the root cause of underestimation the discrete case is likely to be the
most severely affected. In the discrete outcome setting the issues of estimation in the presence of
separation (perfect agreement between two discrete outcomes) is one that might have a large impact
on results. Our simulations did not consider small trial sizes where separation is likely to be
a substantial issue; however, this important topic should be considered in more detail alongside
Figure 1. CLOTS3 case study results: Graphical display of information theory surrogacy estimates for binary DVT surrogate and
ordinal OHS true outcome; study centre size categorised by the terciles of centre size. The regression line represents the regression
of the treatment effects on the true outcome on those for the surrogate. Analysed using a modified information theory approach
incorporating a penalized likelihood approach (Firth 1993) to deal with the issue of sparse data.
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potential solutions. Equally, it would be worth establishing if the overfitting witnessed in the case of
weak surrogacy is systemic to all settings of the information theory approach.
Overall results from the simulation show that the information theory approach works well in
general in the binary-ordinal context, although some issues concerning the two stage nature of the
modelling approach for R2ht have been identified. Methodologically we have seen that across settings
the information theory approach is readily applied and provides a consistent interpretation. The
methodological extensions reported here will enable researchers working in clinical areas where
ordinal outcomes are important to investigate surrogacy. This work provides further confirmation
that information theory is a practical and methodologically sound approach to surrogacy evaluation.
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